Susan Hasty, Publisher
Table of Contents . . . March 5th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Cancer Weekly | Other Publications
Cancer Therapy - Retinoic acid might be of more harm than benefit to cancer patients
Leukemia - Tumor suppressor genes can block leukemic cell proliferation
Breast Cancer - NCI publishes statement on mammography screening
Diagnostic Imaging - Contrast agent improves some aspects of visualizing tumor vascularity
Non-Hodgkin Lymphoma - Autologous stem cell grafts alter Th1/Th2 balance
Tumor Factors - Reduced levels of extracellular enzyme may actually promote cancer growth
Uveitis - Cancer-causing drug safe and effective in treating eye disease
Breast Cancer - New treatment uses radiation alternative
Breast Cancer - Study finds letrozole tablets more effective than anastrozole in inhibiting estrogen production in advanced disease
Breast Cancer - Women with advanced disease sought for unique study at UCLA
Chemotherapy - Viral vector aids therapies that cause cellular suicide
Drug Development - Comprehensive platform being developed for chemoinformatics
Drug Discovery - First milestone achieved in agreement for CD46 human antibodies against cancer
Funding - Immunicon completes $29M private equity offering
Information Technology - Strategic alliance to link cancer treatment network with tumor registry software
Melanoma - Cancer vaccine receives FDA fast track designation
Oral Cancer - Zila previews ViziLite Oral Examination test kit
Ovarian Cancer - AltaRex announces additional phase IIb results for OvaRex
Ovarian Cancer - Blood test may catch disease in early stages
Ovarian Cancer - Phase III clinical trial of Actimmune begins enrollment
Pancreatic Cancer - Inhibitor TIMP-1 a potential gene therapy target for cancer of pancreas
Prostate Cancer - Prevention trial will use selenium and vitamin E
Radiosurgery - M.D. Anderson Cancer Center Orlando to wield powerful weapon against tumors
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.